Sensyne Health plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sensyne Health plc
VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
- Digital Health
- Monitoring Equipment & Devices
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Drayson Health Ltd